PRAZOSIN
-
| StockNo |
Product description |
Status |
| EB0280-424-17 |
PRAZOSIN
TABL 1 MG X 50 |
 |
| EB0280-424-34 |
PRAZOSIN
TABL 2 MG X 50 |
|
| EB0280-424-35 |
PRAZOSIN
TABL 5 MG X 50 |
|
-
- COMPOSITION:
Prazosin hydrochloride 1 mg; 2 mg and 5 mg in one tablet
ACTION:
An antihypertensive drug from the group of peripheral vasodilators.
Its action consists in blocking of the postsynaptic
alpha-1-adrenoreceptors. It inhibits phosphodiesterase activity. It
reduces vascular resistance. unlike the other alpha-adrenoblockers.
It very rarely causes tachycardia. Prazosin has no effect on lipid
metabolism, particularly on low-density lipoproteins. It has no
negative effect on the renal function, but in high doses it slightly
inhibits the central nervous system.
PHARMACOKINETICS:
Prazosin is quickly absorbed, about 80 % of the dose administered.
The maximum plasma concentration is attained after 1-3 h. Its
biological half-life is 2-3 h and its therapeutic action lasts for
8-10 h.
INDICATIONS:
Various forms of hypertension - as an individual therapeutic agent
or in combination with other antihypertensive drugs: treatment of
chronic cardiac insufficiency (in cases of resistance to digitalis
treatment); Raynaud's syndrome and disease.
CONTRAINDICATIONS:
Hypersensitivity; angina pectoris; congestive cardiac insufficiency
caused by obstructive processes. To be cautiously administered in:
impaired renal function and pregnant women and breast feeding
mothers (only after evaluation of the risk factors). It is not
prescribed to children aged below 12 years.
|
SIDE EFFECTS:
Orthostatic hypotension is likely to occur 30 min to 2 h after the
initiation of the treatment or after the successive increase of the
dose. It is permanent in some of the patients during the whole
treatment course, being more frequently observed in elderly
patients, in patients with reduced volume of circulating blood and
those subjected to salt-free diet. Tachycardia is another symptom of
the cardiovascular system. It should be administered very cautiously
in angina pectoris, as the cardiac blood supply can be impended,
with cardiac infarction as a possible complication. The following
symptoms can be observed from the central and peripheral nervous
system: headache, asthenia, dizziness, restlessness, depression.
The other organs can manifest the following symptoms: urine
incontinence; urticaria and bullous rashes; nausea, vomiting,
abdominal pain, diarrhea, dyspersia; anemia, leukopenia.
PRECAUTIONS:
Driving and operating of devices that require particular attention
should be avoided during Prazosin treatment.
DRUG INTERCATIONS:
Non-steroid antiphlogistic agents can reduce the antihypertensive
effect of Prazosin, and estrogens can elevate the blood pressure
during simultaneous administration. Sympathomimetics reduce the
antihypertensive effect. Prazosin should not be administered in
parallel with dopamine and epinephrine.
DOSAGE AND ADMINISTRATION:
The treatment is initiated with 0.5-1 mg. During the following days:
to 2-3 doses of 0.5-1 mg daily are prescribed, in severe cases- to
15 mg daily.
MEDICINAL FORM AND PACKAGE:
Packages with 50 tablets of 1 mg, 2 mg and 5 mg.
STORAGE:
At moderate temperature (15-30° C) in a place protected from
moisture and light.
EXPIRY:
3 (three) years.
|
